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85
86Patients with inflammatory bowel diseases (IBD) have increased risks of dysplasia and colitis-
associated cancer (CAC). We evaluated the risk of development of high-grade dysplasia (HGD)
or CAC after diagnosis of dysplasia using data from a national cohort of patients with IBD.87
88METHODS:89
90
91We performed a multicenter retrospective analysis of data collected from 7 tertiary referral
regional or academic centers in Belgium. In searches of IBD pathology databases, we identified
813 lesions (616 low-grade dysplasias [LGDs], 64 high-grade dysplasias [HGDs], and 133 CACs)
in 410 patients with IBD: 299 had dysplasia (73%) and 111 had CAC (27%). The primary aim










102Of the 287 patients with LGD, 21 (7%) developed more-advanced lesions (HGD or CAC) after a me-
dian time period of 86 months (interquartile range, 34–214). Of the 28 patients with HGD, 4 (14%)
developed CAC after amedian time period of 180months (interquartile range, 23–444). The overall
cumulative incidence of CAC at 10 years after an initial diagnosis of HGD was 24.3% and after an
initial diagnosis of LGDwas 8.5% (P < .05). Metachronous lesions, non-polypoid lesions, and colonic
stricturewereassociatedwith riskofoccurrenceofmore-advanced lesionsafter LGD(P< .05). Of the
630 dysplastic lesions identified during endoscopy, 545 (86%) were removed during the same
procedureorduringa follow-upendoscopyorbysurgery.Of111patientswithCAC, 95 (86%)didnot
have prior detection of dysplasia and 64 of these 95 patients (67%) developed CAC outside of the
screening or surveillance period recommended by the European Crohn’s and Colitis Organisation.103
104CONCLUSIONS:105
106
107In an analysis of pathology data from 7 medical centers in Belgium, we found a low rate of
detection of more-advanced lesions following detection of LGD or HGD—taking into account
that most of the lesions were removed. Main risk factors for development of more-advanced
lesions after LGD were metachronous lesions, non-polypoid lesions, and colon strictures.108
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What You Need to Know
Background
Patients with inflammatory bowel diseases (IBD)
have increased risks of dysplasia and colitis-
associated cancer (CAC). We evaluated the risk of
development of high-grade dysplasia (HGD) or CAC
after diagnosis of dysplasia using data from a na-
tional cohort of patients with IBD.
Findings
In an analysis of pathology data from 7 medical
centers, we found a low rate of detection of more
advanced lesions following detection of LGD or
HGD—taking into account that most of the lesions
were removed. Main risk factors for development of
more advanced lesions after LGD were metachronous
lesions, non-polypoid lesions, and colon strictures.
Implications for patient care
Description of long-term outcome of endoscopically
visible lesions removed by endoscopy or surgery and
identification of risk factors for development of more
advanced lesions could help increase awareness and
adherence of clinicians to international guidelines in
screening or surveillance endoscopy programs and in
detection or treatment modalities of dysplasia.







































































































219Patients with inflammatory bowel disease (IBD)(Crohn’s disease [CD] and ulcerative colitis [UC]) are
at increased risk of colorectal cancer (CRC), namely colitis-
associated colorectal cancer (CAC).1,2 Carcinogenesis in
IBD follows the inflammation-dysplasia-cancer sequence
from inflammation to indefinite, low-grade dysplasia
(LGD), high-grade dysplasia (HGD), with some progressing
to cancer.3 Screening/surveillance colonoscopy is therefore
recommended to detect and treat dysplasia.
Recent meta-analysis reported a 2-fold risk of devel-
oping CAC compared with the general population.4 The
pivotal role of inflammation is supported by disease dura-
tion, extent, and activity (both endoscopically and histo-
logically) as main risk factors for developing CAC.1,5,6
Primary sclerosing cholangitis (PSC),7 family history of
CRC,8 post-inflammatory polyps,9 and dysplasia at colo-
noscopy surveillance represent additional risks factors.
A few recent studies suggest decreasing incidence
and mortality rates of CAC that may be related to
improved IBD patient management, increased adherence
to screening/surveillance recommendations, and
enhanced quality criteria in performing colonoscopy and
detecting/removing lesions.10 CAC originates from either
flat (endoscopically invisible) or raised (visible)
dysplastic lesions as precursor lesions.11 Detection of
dysplasia relies on both pathologic examination from
random biopsies to identify invisible dysplasia and from
targeted biopsies of visible (polypoid and non-polypoid)
lesions. With the improvement of endoscopic techniques,
most dysplastic lesions discovered in IBD patients are
reported to be visible.12
The reported risk of CAC associated with HGD or LGD
varies greatly between studies.13–16 Few studies have
looked at the long-term outcome of endoscopically
visible lesions removed by endoscopy. In nearly all
studies, the treatment status is not even reported, and
this might partly explain the different rates and risks of
progression of dysplasia to more advanced lesion across
these studies. Moreover, the term progression used in all
studies is somewhat confusing when visible resectable
lesions are for the most part removed as recommended
in the management of dysplasia in IBD.
The aim of the study was to evaluate the risk of devel-
opment of more advanced lesions after diagnosis of LGD or













This large national cohort study is a long-term
follow-up retrospective study conducted across 7
Belgian tertiary centers within the Belgian Inflammatory
Bowel Disease Research and Development Group. Pa-
tients with histologically confirmed IBD who were
diagnosed with at least 1 episode of dysplasia and/or
CAC between January 1, 1990 and December 31, 2016
were retrospectively identified through IBD and pa-
thology databases after Ethics Committee agreementFLA 5.6.0 DTD  YJCGH56571_proof (reference number: P2013/331 approved February 25,
2014). Endoscopic, histologic, and clinical data were
collected by electronic chart review. All authors had
access to the study data and had reviewed and approved
the final manuscript. Advanced neoplasia was defined as
HGD or CAC and did not refer to the size, number, and
villous content of the neoplasia. Patients were classified
according to the most advanced lesion that the patients
developed during colonoscopy or at surgery performed
during their follow-up (Supplementary Materials).
Characterization of the Dysplastic/Colitis-
associated Colorectal Cancer Lesions
Each episode of dysplasia was graded according to
the 1983 Inflammatory Bowel Disease Dysplasia
Morphology Study group classification in LGD or HGD.17
Lesions indefinite for dysplasia were excluded. Because
of poor interobserver agreement in grading dysplasia
among pathologists,18 central review has been done by
an independent expert IBD pathologist (P.D.). Lesions
were categorized according to their macroscopic shape
reported on endoscopy report. The Paris19 or SCENIC20
classifications could not always be applied because of
incomplete endoscopy reports. Therefore, lesions were
defined as follows: Visible lesions include polypoid le-
sions (Paris type 0-I lesions) and non-polypoid lesions
(Paris type 0-II, 0-III, irregular, or plate-like lesions);
invisible lesions were defined as absence of documented23 July 2019  3:44 pm  ce CLR




tory bowel disease; LGD,
low-grade dysplasia.Q5













































































































341endoscopic abnormalities. Outside diseased area lesions,
duplicates, misdiagnosed lesions, and recurrence were
defined in Supplementary Materials. Screening/surveil-
lance periods, namely the starting time of screening after
IBD diagnosis and the interval of endoscopic surveil-
lance, were defined according to European Crohn’s and
Colitis Organisation (ECCO) guidelines.21 Patients were
stratified as high, intermediate, or low risk according to
those recommendations. Lesions were diagnosed outside
screening/surveillance period when diagnosed before
screening period or out of screening/surveillance period.
Lesions were diagnosed out of screening/surveillance
period when screening colonoscopy was not performed
on time or when intervals between surveillance colo-
noscopies were too long according to the risk stratifica-
tion profile (Supplementary Materials). The term
development was used on purpose in this study rather
than “progression” used in all studies. In this study,
development of more advanced lesion can be either a
newly developed lesion or a recurrence when the index
lesion has been removed, and progression to more
advanced lesion was used when index lesion has been
left untreated. Therefore, resected and unresected le-







Data were analyzed using MedCalc Statistical Soft-
ware (version 18.5; MedCalc Software bvba, Ostend,
Belgium). Continuous variables were reported asFLA 5.6.0 DTD  YJCGH56571_proof medians with interquartile ranges (IQRs) or ranges
(minimum-maximum). Comparisons of continuous vari-
ables were performed by using Mann-Whitney or
Kruskal-Wallis test. Categorical variables were reported
as numbers (n) and proportions (%). Comparisons of
categorical variables were performed by using Fisher
exact test or Pearson c2 test for trend. Results of logistic
regression were expressed in odds ratios with 95%
confidence intervals (CIs). Rates of development of more
advanced lesion were analyzed using Kaplan–Meier
survival analysis. Comparison of incidences was per-
formed by using log-rank test. Results of Cox propor-
tional hazards regression were expressed in Exp(b) and
95% CI for Exp(b). Exp(b) can be interpreted as the
instantaneous relative risk (RR) of an event, at any time,




A total of 549 IBD patients were diagnosed with LGD,
HGD, or CAC between January 1, 1990 and December 31,
2016 (Figure 1). After exclusion of some patients and
lesions (Supplementary Materials), patients were
grouped according to the location of lesions within or
outside diseased area. Finally, 410 IBD patients with 813
lesions inside diseased area from 645 procedures were
included in the study.23 July 2019  3:44 pm  ce CLR












































































Demographics and clinical variables of the study
population are summarized in Table 1. Among UC pa-
tients, 5 (2%) had proctitis, 68 (27%) had left-side co-
litis, and 175 (71%) had pancolitis. As of December 31,
2016, 266 patients (65%) were still under follow-up
(median, 70 months; IQR, 35–122), 60 patients (15%)
died (median, 36 months; IQR, 6–85) (CAC [n ¼ 32] and
non-CAC [(n ¼ 28] related mortality), and 84 patients
(20%) were lost to follow-up (median, 40 months; IQR,
11–90). Of the 410 patients, 299 (73%) had only
dysplasia (266 LGDs and 33 HGDs), whereas 111 (27%)
had CAC during their follow-up. When comparing pa-
tients with CAC with those with dysplasia (LGD and
HGD), median age at IBD diagnosis was lower (29 [IQR,





Type of IBD, n (%)
- CD 162 (39)
- UC 248 (61)
Male, n (%) 248 (60)
Age (y) at IBD diagnosis, median (IQR) 37 (26–53)
(n ¼ 394)




Deceased, n (%) 60 (15)
Smoking status, n (%)
- Active 36 (9)
- Stopped 88 (21)
- No 139 (34)
- Unknown 147 (36)












No. of neoplastic lesions per patient during
follow-up, median (IQR; range)
1 (1–2; 1–12)
(n ¼ 410)
No. of neoplastic lesions diagnosis procedures




Metachronous lesions, n (%) 132 (32)
(n ¼ 410)
Multifocal lesions, n (%) 117 (29)
(n ¼ 410)
Family history of CRC, n (%) 36 (9)
- First degree - 15
- Other degree - 20
- Unknown - 1
(n ¼ 410)
Associated PSC, n (%) 39 (10)
(n ¼ 410)
CAC, colitis-associated colorectal cancer; CD, Crohn’s disease; CRC, colorecta
interquartile range; LGD, low-grade dysplasia; PSC, primary sclerosing cholangit
aP value for two-sided c2 test or Kruskal-Wallis test. Bold values are significant.
FLA 5.6.0 DTD  YJCGH56571_proof IBD disease duration at time of detection of index lesion
was longer (19 [IQR, 10–28] vs 10 (IQR, 2–19] years; P <
.0001). There were more metachronous (39% vs 29%;
P ¼ .036) and multifocal synchronous lesions (38% vs
24%; P ¼ .004) among patients with advanced neoplasia
(HGD or CAC) compared with those with LGD.
Lesion Characteristics
Characteristics of the 813 dysplasia/CAC lesions are
summarized in Table 2. Six hundred sixteen lesions were
LGDs, 64 HGDs, and 133 CACs. Most of the lesions were
endoscopically visible lesions (92%) that include
polypoid (64%) and non-polypoid (36%) lesions. LGD
lesions were more likely to be invisible than advanced
neoplasia lesions (57/616, 9% vs 6/197, 3%; P ¼ .003).










99 (37) 9 (27) 54 (49)
167 (63) 24 (73) 57 (51)















20 (8) 4 (12) 36 (32) <.01
NS
24 (9) 1 (3) 11 (10)
57 (21) 7 (21) 24 (22)
90 (34) 12 (36.5) 37 (33)


















































28 (11) 1 (3) 7 (6) NS
- 13 - 0 - 2














l cancer; HGD, high-grade dysplasia; IBD, inflammatory bowel disease; IQR,
is; UC, ulcerative colitis.





























































































































547non-polypoid (151/191, 79% vs 121/559, 22%; P <
.0001) and 1 cm than LGD lesions (117/127, 92% vs
118/422, 28%; P < .0001) (Supplementary Materials for
risk factors associated with CAC.)
Diagnosis of Dysplasia and Colitis-associated
Colorectal Cancer
Fourteen patients (3%) had their first lesion diag-
nosed before IBD diagnosis, 27 (7%) at IBD diagnosis,
111 (27%) before 8 years of disease, and 22 (5%) be-
tween 8 and 10 years of disease. In total, 37% and 42%
of the patients had their first lesion diagnosed before 8
and 10 years of disease, respectively. Seventy-six CACs
(57%) were diagnosed during colonoscopy and 57
(43%) at surgery. Four CACs (3%) were diagnosed
before IBD diagnosis, 4 (3%) at IBD diagnosis, 8 (6%)
before screening period, 59 (44%) during screening/
surveillance period, and 58 (44%) out of screening/
surveillance period according to ECCO recommendations.
Seventeen percent and 21% of the patients had their CAC
diagnosed before 8 and 10 years of disease, respectively
(Supplementary Materials for more details about diag-








555Treatment of Dysplasia and Colitis-associated
Colorectal Cancer
Among the 630 dysplastic lesions reported during
endoscopy, the majority were removed at the time of the
endoscopy detection (436/630, 69%) or at a second





- Visible 750 (92%)
- Invisible 63 (8%)
For visible lesions
- Polypoid 478 (64%)
- Non-polypoid 272 (36%)
Size of the lesion
- <1 cm 235 (31%)
- 1 cm 314 (42%)
- Unknown 201 (27%)
Diagnosis circumstances
- Colonoscopy 706 (87%)
- Surgery 107 (13%)
Treatment status of lesions
diagnosed during endoscopy
- During the same procedure 443 (63%)
- During a second procedure 168 (24%)
- No treatment 71 (10%)
- Unknown 24 (3%)
CAC, colitis-associated colorectal cancer; HGD, high-grade dysplasia; LGD, low-
aP value for two-sided c2 test. Bold values are significant.
FLA 5.6.0 DTD  YJCGH56571_proof 17%), whereas only a minority were left untreated (61/
630, 10%) or had an unknown treatment status (24/630,
4%) (Supplementary Materials for more details). Median
duration between diagnostic and second procedure was
significantly longer for LGD lesions compared with HGD
lesions (103 [IQR, 58–240] vs 48 days (IQR, 40–123);
P ¼ .0039). Concerning the 76 CACs that were diagnosed
during colonoscopy, 59 (78%) had surgery secondarily
after a median duration of 35 days (IQR, 21–105).
Rate of Development to More Advanced
Lesions
Two hundred eighty-seven patients were initially
diagnosed with LGD, 28 with HGD, and 95 with CAC.
Table 3 and Figure 2 show the most advanced lesion that
the patients developed during colonoscopies or at sur-
gery performed during follow-up after the index lesion
was diagnosed, according to the grade of this lesion.
Twenty-one of 287 patients (7%) who were initially
diagnosed with LGD developed more advanced lesions (9
HGDs and 12 CACs) after a median time of 86 months
(IQR, 34–214) (137 [IQR, 40–232] for CAC vs 43 [IQR,
12–118] for HGD; P ¼ .0466), whereas 202 of 287 (71%)
did not develop any further lesion. Four of 28 patients
(14%) who were initially diagnosed with HGD developed
CAC after a median time of 180 months (IQR, 23–444),
whereas 15 of 2 (54%) did not develop any further
lesion (Supplementary Materials for more details).
Sixteen patients (14%) (12 with prior LGD, 4 with prior
HGD) developed CAC secondarily after a median follow-
up of 137 months (IQR, 39–260), whereas 95 (86%)









559 (91%) 58 (91%) 133 (100%)
57 (9%) 6 (9%) 0 (0%)
<.01
438 (78%) 29 (50%) 11 (8%)
121 (22%) 29 (50%) 122 (92%)
<.01
118 (21%) 25 (43%) 92 (69%)
304 (54%) 9 (16%) 1 (1%)
137 (25%) 24 (41%) 40 (30%)
<.01
576 (94%) 54 (84%) 76 (57%)
40 (6%) 10 (16%) 57 (43%)
<.01
410 (71%) 26 (48%) 7 (9%)
89 (15%) 20 (37%) 59 (78%)
55 (10%) 6 (11%) 10 (13%)
22 (4%) 2 (4%) 0 (0%)
grade dysplasia.


























Table 3. Findings on Follow-up Colonoscopies and Surgery
Based on Index Lesion (Number of Patients)
Index lesion
Most advanced follow-up lesion
No dysplasia
or CAC LGD HGD CAC Total
LGD 202 (71%) 64 (22%) 9 (3%) 12 (4%) 287
HGD 15 (54%) 7 (25%) 2 (7%) 4 (14%) 28
CAC 77 (81%) 5 (5%) 3 (3%) 10 (11%) 95
Total 294 76 14 26 410
CAC, colitis-associated colorectal cancer; HGD, high-grade dysplasia; LGD,
low-grade dysplasia.




























































































672detected dysplasia. Sixty-seven percent of the patients
diagnosed with CAC without prior detected dysplasia
were diagnosed outside screening/surveillance period.
Details are described in Supplementary Materials.
Whereas 25 of 315 patients (8%) with LGD or HGD as
index lesion developed more advanced lesion, 290 of 315
patients (92%) with LGD or HGD did not develop more
advanced lesion (Supplementary Materials for more de-
tails about completeness of follow-up).
Overall cumulative incidence of HGD or CAC devel-
opment at 1 and 10 years after initial LGD diagnosis was
2.3% (standard error [SE], 1%) and 13.8% (SE, 3.2%),
respectively (Figure 3A). Rate of development of CAC
was higher after HGD compared with LGD (P ¼ .0364)
(Figure 3B), with an overall cumulative incidence of CAC
development at 1 and 10 years after LGD diagnosis of
0.5% (SE, 0.5%) and 8.5% (SE, 2.7%), respectively,
whereas at 1 and 10 years after HGD diagnosis it was





678Risk Factors Associated With the Development
of More Advanced Lesions
In univariate analysis, metachronous lesions
(P ¼ .0003), multifocal lesions (P ¼ .0014), non-polypoidFigure 2. CAC, colitis-associated colorectal cancer; HGD,
high-grade dysplasia; LGD, low-grade dysplasia.
FLA 5.6.0 DTD  YJCGH56571_proof lesions (P < .0001), associated PSC (P ¼ .0032), invisible
lesions (P ¼ .0048), and colonic stricture (P < .0001)
were associated with the risk of development of more
advanced lesions. In multivariate analysis, metachronous
lesions (P ¼ .0119), non-polypoid lesions (P ¼ .0006),
and colonic stricture (P ¼ .0496) remained associated
with the risk of development of more advanced lesions
(Supplementary Table 4) (Supplementary Materials for



















This large national cohort study revealed that the rate
of development of more advanced lesions after LGD was
low (7%), and only 14% of the patients who were
initially diagnosed with HGD developed CAC, considering
that nearly all lesions had been removed. Most of the
dysplastic lesions diagnosed during endoscopy were
treated during the same procedure or at a second follow-
up by endoscopy or surgery (86%). Main risk factors for
development of more advanced lesion were the presence
of metachronous lesions, non-polypoid lesions, and
colonic stricture. Advanced neoplasia lesions were more
likely to be visible, non-polypoid, 1 cm, metachronous,
and multifocal synchronous than LGD lesions. Our rate of
invisible LGD lesions (9%) is close to the one reported in
SCENIC consensus20 (9.4% by high definition white light
endoscopy and 9.8% by chromoendoscopy [CE]) or in
study by Choi et al22 (9.3%). Importantly, the majority of
IBD patients with CAC (86%) were diagnosed without
prior detected dysplasia, mainly because of outside
screening/surveillance period for 67% of them.
The SCENIC international consensus statement on
surveillance of dysplasia in IBD20 recommends complete
endoscopic removal of resectable polypoid dysplastic le-
sions, followed by surveillance colonoscopy. However, in
addition to poor reproducibility of Paris classification23
and no validation in IBD, it is not clear that the risk of
CAC is the same for visible and invisible dysplastic lesions
and for polypoid andnon-polypoid dysplastic lesions. Very
few studies have looked at long-term outcome of visible
lesions removed by endoscopy because there are limited
follow-up data especially for non-polypoid lesion resected
by endoscopic submucosal dissection.24 In many studies,
treatment status is not even reported, and this might
partly explain the different incidence rates for more
advanced lesions across these studies in which CAC inci-
dence was between 2% and 13% after a mean follow-up
period of 36–82 months.13–15 In our study, overall cu-
mulative incidence of HGD or CAC development at 1 year
after initial LGD diagnosis was 1.9%, which is much lower
than the incidence of 10.9% at 1 year previously re-
ported.22 This difference can be explained by the fact that
we excluded all misdiagnosed lesions. Indeed, median
time to progression varied from 10.5 to 13 months,22
depending on whether LGD lesions on biopsies from23 July 2019  3:44 pm  ce CLR
Figure 3. CAC, colitis-associated colorectal cancer; HGD,
high-grade dysplasia; LGD, low-grade dysplasia.




















































































































812colonoscopy progressed to CAC or HGD. This short time of
progression suggests more hidden or missed HGD or CAC
at the time of colonoscopy than real progression from LGD
lesions. Such lesionswere reported in our study directly as
HGD or CAC diagnosed at surgery performed for preex-
isting dysplasia (even if LGD) on biopsies from colonos-
copy. Also, those patientswere considered to be diagnosed
with HGD or CAC without evidence of prior dysplasia
because this is the same lesion (misdiagnosed lesion);
indeed, the time between colonoscopy and surgery is very
short (median, 57 days). This may explain why 86% of the
patients with CAC were diagnosed without evidence of
prior dysplasia, whereas 14% developed CAC secondarily
after a median follow-up of 137 months. Our results are
therefore more in concordance with those reported in 2
meta-analyses.4,16 Thus, patients with IBD have a low risk
of development of more advanced lesions after resection
of dysplastic lesions.
Although many studies have examined risk factors
associated with CAC, very few have examined risk factors
associated with the risk of development of more
advanced lesion after diagnosis of dysplasia. We haveFLA 5.6.0 DTD  YJCGH56571_proof shown that in IBD patients, non-polypoid lesions are the
most important risk factor of development of CAC with a
RR of 15, which is consistent with another study.22 They
reported that dysplastic lesions that are non-polypoid,
endoscopically invisible, 1 cm, or preceded by indefi-
nite dysplasia were associated with increased risk of
progression to advanced lesion. Previous studies have
shown that patients with polypoid LGD lesions have a
low risk of development of CAC.25 PSC was also an
important risk factor (3.4-fold increase) in our study to
the same extent as in the meta-analysis by Fumery et al,4
where invisible dysplasia and multifocal dysplasia were
also significantly associated with progression to
advanced lesion.
Dysplasia is a reliable marker for the risk of devel-
oping or having CAC. Indeed, when indication of surgery
was HGD, 42% of the patients had CAC in their surgical
specimen. For those who had colectomy for LGD, more
advanced lesions were found in 23% of cases (CAC in
19% of cases). This is a little lower than the percentages
reported by Choi et al22 (46% and 39%, respectively). In
the meta-analysis by Fumery et al,4 30% of the patients
who underwent colectomy for LGD had more advanced
lesions. Yet, CAC can develop in patients without history
of dysplasia or from invisible dysplastic lesions. Also, not
all patients with LGD may pass through a phase of
detectable HGD before developing CAC.26 In this cohort,
86% of patients were diagnosed with CAC without prior
detected dysplasia. This can be easily explained with
67% of them diagnosed outside screening/surveillance
period; dysplasia had therefore not been previously re-
ported in these patients. Previous colonoscopies may
have been false negative in patients diagnosed with CAC
inside screening/surveillance period because of subop-
timal conditions (eg, inflammation, low rate of CE/
random biopsies performed, and poor colonic prepara-
tion). Low quality endoscopy measures may likely play a
role and are difficult to evaluate because of the retro-
spective design of the study. Nevertheless, only 57% of
CACs were diagnosed during colonoscopy. When CAC
was diagnosed at surgery, surgery was initially per-
formed for detected preexisting neoplasia in only 56% of
the cases. Thus, low rate of detected preexisting
neoplasia heralds the need for improved training in the
detection of dysplastic lesions.
Most cases of CACs are believed to arise from
dysplasia. Endoscopic screening/surveillance guidelines
have been developed to enable the detection and po-
tential removal of precancerous lesions. This strategy
aims at decreasing the incidence of CAC and related
mortality.27 However, we and others have shown that
CACs are most often detected outside screening/sur-
veillance period: at IBD diagnosis, before or out of
screening/surveillance period. In a princeps study,28
only 25 of 149 patients (17%) were diagnosed with
CAC during screening/surveillance period, and 22%
developed CAC before 8 or 15 years of surveillance for
pancolitis and left-side colitis, respectively. Eleven23 July 2019  3:44 pm  ce CLR



































































































911percent of CACs were diagnosed before screening period
and 17% before 8 years of disease in our cohort. Today,
several guidelines recommend starting surveillance after
8–10 years of first symptoms.21,26 In the CESAME
cohort,29 colonoscopy surveillance rate was surprisingly
low in IBD patients with longstanding extensive colitis,
with only 54% of the patients who had at least 1 sur-
veillance colonoscopy during the study period. Thus, the
high rate of CACs outside screening/surveillance period
in all the studies might be explained by poor adherence
in routine practice to screening/surveillance programs
according to recommendations.
This study has several limitations. This is a retro-
spective study. We may underestimate the risk of
development of more advanced lesions because of high
number of CACs diagnosed without evidence of prior
dysplasia and outside screening/surveillance period.
This means that we can assume that if they had had
proper surveillance, it is possible that dysplastic lesions
would have been identified before the CAC diagnosis. The
consensus statement by Rutter et al30 could help to
better define diagnostic circumstances of neoplastic le-
sions to limit the occurrence of interval lesions in the
future management of dysplastic lesions in IBD.
In conclusion, the rate of development of more
advanced lesion after LGD is low in patients in whom the
majority of the lesions have been routinely removed.
This reassuring real-life data must be balanced with the
high rate of patients diagnosed with CAC without
detected preexisting dysplasia. This heralds the need for
improved training in the detection of dysplastic lesions,
together with increased awareness of colon cancer
screening and surveillance in IBD patients.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
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The Pathology database was established by using the
International Classification of Diseases 9th revision code
for the identification of IBD patients and neoplastic le-
sions, with additional chart review performed to confirm
IBD diagnosis. We optimized case retrieval by double
cross-check through hand chart review using IBD regis-
tries. Patients with not enough information about their
IBD and/or dysplastic/CAC lesion were excluded as well
as those whose lesion(s) did not show dysplasia or CAC
after central review by an independent expert IBD
pathologist (P.D.). Patients’ demographics, IBD pheno-
typic characteristics, and data regarding IBD-related
therapies were collected. Information on family history
of IBD or CRC was also obtained.
Patients were classified according to the most
advanced lesion during colonoscopy or at surgery per-
formed at follow-up. The index lesion was the first lesion
diagnosed in a patient during colonoscopy or surgery.
When more than 1 lesion was found during the pro-
cedure, we considered the lesion with maximal grade of
dysplasia or CAC. The follow-up lesion is the most
advanced lesion developed at follow-up procedure
(either colonoscopy or surgery) after the index lesion.
When more than 1 dysplasia/CAC lesion was found and
more than 1 procedure was done during follow-up, the
categorization of the follow-up lesion was based on the
maximal grade of dysplasia or CAC. If no lesion was
detected during follow-up, the follow-up lesion is re-
ported as no dysplasia/CAC. Patients were considered to
have multifocal neoplastic lesions when they had more
than 1 lesion during the same procedure. They were
considered to have metachronous neoplastic lesions
when they had more than 1 episode of neoplasia in
minimum 2 procedures during their follow-up.
Patients were considered lost to follow-up if in
December 2016 they had not been seen at their IBD
center for more than 1 year.
Patients were considered to have family history of
CRC if he/she had either first-, second-, or third-degree
relatives who had CRC at any age.
Patients were considered to have associated PSC only
if the diagnosis was confirmed radiologically and/or
histologically.
Characterization of the dysplastic/colitis-associated
colorectal cancer lesions. Only lesions with available
pathologic report after surgery or colonoscopy were
taken into account. Lesions outside diseased area and
lesions where dysplasia or CAC was not confirmed at
review were excluded. A diseased area was defined as a
colonic area that is histologically and/or endoscopically
affected at least once in the follow-up of the patient.
Lesions outside diseased area were therefore lesions
located in a part of the colon that has not been
histologically (even without apparent endoscopicFLA 5.6.0 DTD  YJCGH56571_proof involvement) and/or endoscopically involved. Dupli-
cates, defined as lesions being found either in the same
procedure on different slides (same lesions in same
procedure) or in another procedure that follows the
diagnostic procedure if the lesions have not been treated
or treated incompletely (same lesions in different pro-
cedures), were also excluded. In the same way were
excluded misdiagnosed lesions (same lesions in different
procedures with a different grade of neoplasia), defined
as lesions being found in another procedure that follows
the diagnostic procedure if the lesions have not been
treated or treated incompletely and have a different
grade of neoplasia. Lesions affecting the small intestine
were excluded. Recurrence, defined as a lesion occurring
in the same diseased area as a lesion previously diag-
nosed and treated, was considered as a new lesion and
not as a duplicate in the follow-up of the patient.
Data concerning the diagnostic circumstances (colo-
noscopy or surgery) and the indication of the diagnostic
procedure (eg, surveillance colonoscopy or colonoscopy
for therapeutic management) as well as the treatment of
the lesion either at initial diagnosis procedure or during
a following procedure and the follow-up of untreated
lesions were collected. The treatment was defined as
unknown when it was not specified in the endoscopy
report whether the lesion was resected or not. Infor-
mation about location of the lesions within or outside a
diseased area (active or quiescent) and extension of the
disease (Montreal classification) was also collected. Data
on the presence or absence of a documented episode of
colonic stricture or post-inflammatory polyp were
collected.
ECCO guidelines1,2 were retrospectively applied to
our study population to be able to categorize neoplastic
lesions as diagnosed before, during, or out of screening/
surveillance period. According to ECCO guidelines,
screening colonoscopy should be offered 8 years after
the onset of colitis symptoms to all patients (UC and
Crohn’s colitis) to reassess disease extent and exclude
dysplasia. Patients were stratified as high, intermediate,
or low risk for surveillance interval according to those
guidelines. Ongoing surveillance should be performed in
all patients apart from those with proctitis or Crohn’s
colitis involving only 1 segment of colorectum. Patients
with high risk features (stricture or dysplasia detected
within the past 5 years, PSC, extensive colitis with severe
active inflammation, or a family history of CRC in a first-
degree relative when younger than 50 years) should
have next surveillance colonoscopy scheduled for 1 year.
In patients with concurrent PSC, annual surveillance
colonoscopy should be performed after the diagnosis of
PSC, irrespective of disease activity, extent, and duration.
Patients with intermediate risk factors should have their
next surveillance colonoscopy scheduled for 2–3 years.
Intermediate risk factors include extensive colitis with
mild or moderate active inflammation, post-
inflammatory polyps, or a family history of CRC in a
first-degree relative at 50 years and older. Patients with23 July 2019  3:44 pm  ce CLR



















































































































1275neither intermediate nor high risk features should have
their next surveillance colonoscopy scheduled for 5
years.
Nevertheless, because of the difficulty of retrospec-
tively determining the onset of colitis symptoms in all
patients, it was the disease diagnosis rather than the
onset of symptoms that was considered to define the
screening period, namely the starting time of screening
after disease diagnosis.
Lesions were diagnosed out of screening/surveillance
period when screening colonoscopy was not performed
on time (more than 8 years after disease diagnosis) or
when intervals between surveillance colonoscopies were
too long according to the risk stratification profile (more
than 1 year in high risk patients, 3 years in intermediate
risk patients, and 5 years in low risk patients). Lesions
were diagnosed outside screening/surveillance period
when diagnosed before screening period (before 8 years
after the disease diagnosis) or out of screening/surveil-
lance period.
Results
Study population. Eight patients were excluded for
the following reasons: no neoplasia after pathology re-
view (n ¼ 6), no IBD (n ¼ 1), and lack of clinical infor-
mation (n ¼ 1). Among the 541 remaining patients, 1443
lesions were identified. Two hundred sixty lesions were
excluded for the following reasons: no neoplasia after
pathology review (n ¼ 21), same lesion in same pro-
cedure (n ¼ 36), same lesion in different procedures
(n ¼ 142), ileal location of the lesion (n ¼ 7), lack of
clinical/pathologic information (n ¼ 14), and mis-
diagnosed lesion (n ¼ 40).
Risk factors associated with colitis-associated
colorectal cancer. In univariate analysis performed by lo-
gistic regression, CD, younger age at IBD diagnosis, and
longer follow-up duration after IBD diagnosis were signif-
icantly associated with the risk of developing a CAC,
whereas in multivariate analysis, younger age at IBD diag-
nosis and longer follow-up duration after IBD diagnosis
remained statistically significant (Supplementary Table 1).
Diagnosis of dysplasia and colitis-associated colorectal
cancer. Ninety-four percent of LGDs were diagnosed
during colonoscopy performed for IBD diagnosis in 6%
of the cases, therapeutic management in 19% of the
cases, screening in 11% of the cases, and surveillance in
64% of the cases. Eighty-four percent of HGDs were
diagnosed during colonoscopy performed for IBD diag-
nosis in 7% of the cases, therapeutic management in
32% of the cases, screening in 9% of the cases, and
surveillance in 52% of the cases. Fifty-seven percent of
CACs were diagnosed during colonoscopy performed for
IBD diagnosis in 2% of the cases, therapeutic manage-
ment in 54% of the cases, screening in 5% of the cases,
and surveillance in 39% of the cases.
Chromoendoscopy was performed in 15% of the pa-
tients, and 32 random biopsies were performed in lessFLA 5.6.0 DTD  YJCGH56571_proof than 1% of the patients. Method of resection as well as
completeness of resection was specified in less than 50%
of the endoscopy reports. For this reason, it was assumed
that in case of resection and in the absence of additional
precision, the lesions were completely resected.
Indications for surgeries when colitis-associated
colorectal cancer was diagnosed at surgery. Regarding
indications for surgery when CAC was diagnosed at
surgery, surgery was initially performed for preexisting
dysplasia on the biopsies from a colonoscopy in 22 CACs
(39%) (13 preexisting HGDs, 9 preexisting LGDs), of
which 10 had an associated stricture (5 HGDs and 5
LGDs). Those 22 CACs were diagnosed at surgery per-
formed after a median time of 57 days (IQR, 28–86) after
colonoscopy and were part of what we considered as
misdiagnosed lesions. Ten synchronous CACs (18%)
were diagnosed at surgery performed for another CAC
diagnosed during colonoscopy. Surgery was performed
because of a high clinical suspicion of CAC based on
computed tomodensitometry in 7 CACs (12%). The last
18 CACs (33%) were diagnosed at surgery performed for
IBD therapeutic management, mostly stricture (8 CACs)
but also fistula or intra-abdominal collection (3 CACs),
occlusion (3 CACs), refractory disease to medical treat-
ment (1 CAC), and presence of a suspicious mass at
endoscopy with negative pathology (3 CACs).
Indications for surgeries for the entire study
population. Of the study population (n ¼ 410), 194 pa-
tients (47%) underwent 1 or more colonic surgical in-
terventions during follow-up, with a total of 212 surgical
interventions. The indications for surgery and the most
advanced grade of neoplasia found on surgical specimens
for the 194 patients and 212 surgeries are shown in
Supplementary Tables 2 and 3, respectively. Twenty-five
percent of the patients diagnosed with dysplasia (n ¼
78/315; 31 HGDs, 47 LGDs) underwent surgery (partial
or total colectomy) for dysplasia as indication. Histologic
analysis of their surgical specimen revealed CAC in 22
patients (28%), HGD in 7 (9%), LGD in 25 (32%), and no
neoplasia in 24 patients (31%). Overall, when the indi-
cation for surgery was HGD, 42% of the patients (13/31)
had CAC in their surgical specimen. For those who had
surgery for LGD, HGD or CAC was found in 23% of cases
(11/47). Indication for surgery was CAC in 63 surgeries,
of which histologic analysis showed CAC in 59 specimens
(94%), no neoplasia after chemoradiotherapy for rectal
CAC in 1 specimen (1.5%), and dysplasia (2 LGDs, 1
HGD) in 3 specimens (4.5%) after CAC endoscopic
resection. Sixty IBD patients with no previous dysplasia
underwent surgery for therapeutic management (re-
fractory disease, stenosis, fistula, collection) but also for
high clinical suspicion of CAC based on computed
tomodensitometry, and CAC was found on the surgical
specimen in 21 patients (35%), whereas dysplasia was
found in 16 patients (27%) (15 LGDs, 1 HGD).
Treatment of dysplastic/colitis-associated colorectal
cancer lesions. Among the 61 dysplastic lesions left un-
treated, 55 were LGD and 6 HGD. Twenty-nine LGDs23 July 2019  3:44 pm  ce CLR
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1380were visible lesions (7 polypoid, 22 non-polypoid),
whereas 26 were invisible lesions. Five HGDs were
visible lesions (2 polypoid, 3 non-polypoid), and 1 was
invisible lesion. Among the 24 dysplastic lesions with an
unknown treatment status, all were visible lesions, with
17 polypoid (1 HGD, 16 LGD) and 7 non-polypoid lesions
(1 HGD, 6 LGD).
Rate of development of more advanced lesions. Among
the 25 patients (21 LGDs and 4 HGDs) who developed
more advanced lesions during their follow-up, all but 2
were treated previously for their dysplastic lesions.
Indeed, only 2 patients had untreated LGD and pro-
gressed to HGD. One of the LGDs was a non-polypoid
lesion left in place because of limited life expectancy,
and the second one was an invisible lesion.
As of December 2016, 15 of the 290 patients who did
not developmore advanced neoplasia during their follow-
up had total colectomy during follow-up, 49 had no sur-
veillance colonoscopy after index lesion diagnosis, and the
remaining 226 patients had their last surveillance colo-
noscopy after a median follow-up of 55 months (IQR,
25–95). To analyze overall cumulative incidence of HGD
and/or CAC development at 1 and 10 years after LGD or
HGD diagnosis, patients who had total colectomy during
follow-up after index lesion diagnosis and patients who
had no surveillance colonoscopy were excluded.
Diagnostic circumstances of the patients diagnosed
with high-grade dysplasia without prior detected low-
grade dysplasia. Among the 28 patients diagnosed with
HGD without prior LGD, 1 was diagnosed 20 months
before IBD diagnosis with no colonoscopy performed
before; 3 at IBD diagnosis with no colonoscopy per-
formed before; 5 before screening colonoscopy after a
mean time after IBD diagnosis of 65 months (IQR, 53–86)
and with a mean interval to prior colonoscopy of 18
months (IQR, 14–23); 11 during screening or surveil-
lance period according to the risk stratification profile (1
year in high risk patients, 3 years in intermediate risk
patients, and 5 years in low risk patients) with a mean
interval to prior colonoscopy of 18 months (IQR, 14–24);
and 8 out of screening/surveillance period (when
screening/surveillance colonoscopy was not performed
on time (more than 8 years after disease diagnosis or
when intervals between surveillance colonoscopies were
too long according to the risk stratification profile). Most
of the patients diagnosed out of screening/surveillanceFLA 5.6.0 DTD  YJCGH56571_proof period had an inappropriate follow-up, with a mean in-
terval to prior colonoscopy of 8 years (IQR, 7–9). Sixty-
one percent of the patients diagnosed with HGD
without prior LGD were therefore diagnosed outside
screening/surveillance period.
Diagnostic circumstances of the patients diagnosed
with colitis-associated colorectal cancer without prior
detected dysplasia. Among the 95 patients diagnosed
with CAC without prior detected dysplasia, 4 (4%) were
diagnosed before IBD diagnosis with a mean interval
before IBD diagnosis of 31 months (IQR, 12–51) with
either no colonoscopy performed before in 3 patients or
a colonoscopy performed 5 years before the CAC diag-
nosis in 1 patient; 4 (4%) at IBD diagnosis with either no
colonoscopy performed before in 3 patients or a colo-
noscopy performed 13 years before the CAC diagnosis in
1 patient; 8 (8%) before screening colonoscopy after a
mean time after IBD diagnosis of 31 months (IQR, 2–57)
and with a mean interval to prior colonoscopy of 12
months (IQR, 2–25); 31 (33%) during screening or sur-
veillance period according to the risk stratification pro-
file with a mean interval to prior colonoscopy of 15
months (IQR, 4–19); and 48 (51%) out of screening/
surveillance period with a mean interval to prior colo-
noscopy of 8 years (IQR, 2–12).
Risk factors associated with the development of colitis-
associated colorectal cancer after dysplasia. In univariate
analysis, metachronous lesions (P ¼ .0086), multifocal
lesions (P ¼ .005), non-polypoid lesions (P ¼ .0014),
associated PSC (P ¼ .0005), and colonic stricture (P ¼
.0017) were significantly associated with the risk of
development of CAC after dysplasia. In multivariate
analysis, only the presence of non-polypoid lesions (P ¼
.0106) and associated PSC (P ¼ .033) were significantly
associated with the risk of development of CAC after
dysplasia (Supplementary Table 5).23 JReferences
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Supplementary Table 1. Risk Factors Associated With CAC
Variable
Univariate analysis Multivariate analysis
Odds ratio 95% CI P valuea Odds ratio 95% CI P valuea
CD 1.68 1.08–2.60 .02 1.55 0.97–2.46 .07
Age at IBD diagnosis 0.97 0.96–0.99 <.01 0.98 0.97–0.99 .01
Follow-up duration after IBD diagnosis 1.04 1.02–1.06 <.01 1.03 1.01–1.05 <.01
Female 1.00 0.65–1.57 .97
Smoking status 1.08 0.63–1.87 .77
Metachronous lesions 1.07 0.68–1.71 .76
Multifocal lesions 1.29 0.81–2.07 .29
Family history of CRC 0.63 0.27–1.47 .28
Associated PSC 1.58 0.79–3.17 .20
CD, Crohn’s disease; CI, confidence interval; CRC, colorectal cancer; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis.
aP value for logistic regression. Bold values are significant.
Supplementary Table 2. Indication for Surgery During
Follow-up and the Maximal Grade
of Neoplasia Found in Surgical
Specimen (Number of Surgeries)Q6
Indication for surgery
Findings in surgical specimen
No neoplasia LGD HGD CAC Total
LGD 16 22 2 9 (18%) 49
HGD 8 6 5 13 (41%) 32
CAC 1 2 1 59 (94%) 63
Other reason 23 17 1 27 (40%) 68
Total 48 47 9 108 212
CAC, colitis-associated colorectal cancer; HGD, high-grade dysplasia; LGD,
low-grade dysplasia.
Supplementary Table 3. Indication for Surgery During
Follow-up and the Maximal Grade
of Neoplasia Found in Surgical
Specimen (Number of Patients)
Indication for surgery
Findings in surgical specimen
No neoplasia LGD HGD CAC Total
LGD 16 20 2 9 (19%) 47
HGD 8 5 5 13 (42%) 31
CAC 1 2 1 52 (93%) 56
Other reason 23 15 1 21 (35%) 60
Total 48 42 9 95 194
CAC, colitis-associated colorectal cancer; HGD, high-grade dysplasia; LGD,
low-grade dysplasia.
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Supplementary Table 4. Risk Factors Associated With Development of More Advanced Lesion (HGD or CAC)
Variable
Univariate analysis Multivariate analysis
Relative risk 95% CI P valuea Relative risk 95% CI P valuea
Metachronous lesions 14.50 3.39–61.90 <.01 6.99 1.54–31.77 .01
Multifocal lesions 3.99 1.71–9.34 <.01 0.94 0.34–2.59 .90
Non-polypoid lesions 20.94 4.92–89.17 <.01 13.78 3.11–61.19 <.01
Associated PSC 3.78 1.56–9.14 <.01 1.45 0.52–4.03 .48
Invisible lesions 3.18 1.42–7.11 <.01 2.36 0.93–5.99 .07
Colonic stricture 7.48 3.08–18.17 <.01 2.64 1.00–6.96 <.05
Age at IBD diagnosis 0.99 0.97–1.01 .40
Family history of CRC 0.76 0.16–3.69 .73
Smoking status 0.37 0.12–1.17 .09
Age at diagnosis of the index lesion 1.01 0.98–1.03 .71
Family history of IBD 0.58 0.12–2.80 .50
CI, confidence interval; CRC, colorectal cancer; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis.
aP value for Cox proportional hazards regression. Bold values are significant. Q7
Supplementary Table 5. Risk Factors Associated With Development of Colitis-associated Colorectal Cancer
Variable
Univariate analysis Multivariate analysis
Relative risk 95% CI P valuea Relative risk 95% CI P valuea
Metachronous lesions 7.47 1.67–33.42 <.01 3.72 0.76–18.21 .10
Multifocal lesions 5.17 1.64–16.27 <.01 1.44 0.41–5.05 .57
Non-polypoid lesions 26.94 3.55–204.35 <.01 14.96 1.88–119.25 .01
Associated PSC 6.35 2.26–17.85 <.01 3.41 1.10–10.56 .03
Colonic stricture 6.33 2.00–20.00 <.01 1.85 0.5550–6.18 .32
Invisible lesions 2.60 0.94–7.19 .07
Age at IBD diagnosis 0.98 0.95–1.01 .21
Family history of CRC 0.43 0.05–3.62 .44
Smoking status 0.36 0.07–1.77 .21
Age at diagnosis of the index lesion 1.00 0.96–1.03 .92
Family history of IBD 0.89 0.17–4.71 .89
CI, confidence interval; CRC, colorectal cancer; IBD, inflammatory bowel disease; PSC, primary sclerosing cholangitis.
aP value for Cox proportional hazards regression. Bold values are significant.
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